Last week witnessed a strong performance from biotech firm Amgen (AMGN), with an artificial intelligence (AI)-based trading robot facilitating a 4.47% gain. This feat underlines the growing potential of AI in stock market trading. Specifically, the AI trading robot was able to leverage technical analysis, using the Moving Average Convergence Divergence (MACD) indicator, to exploit the inherent market opportunities.
For the uninitiated, the MACD is a trend-following momentum indicator that displays the relationship between two moving averages of a security's price. It involves subtracting the 26-period Exponential Moving Average (EMA) from the 12-period EMA. A nine-day EMA of the MACD, known as the "signal line," is then drawn on top of the MACD, which can function as a trigger for buy and sell signals.
In AMGN's case, the MACD turned positive on July 11, 2023, signaling a potential upward trend. This signal is considered bullish, indicating that it may be an optimal time to purchase shares. Historical analysis supports this: when AMGN's MACD turned positive in the past, the stock continued to rise in 27 out of 41 cases over the subsequent month, suggesting an upward trend continuation probability of 66%.
The AI trading robot capitalized on this signal, generating a profitable return of 4.47% over the course of the week. This was not a random outcome; rather, it demonstrates the efficacy of AI in discerning and acting upon complex market signals in real-time.
AI's success in this context lies in its ability to process vast amounts of data quickly and accurately, something that would take a human trader significantly more time. In addition to speed, AI can consistently apply trading rules without allowing emotions to interfere, a common pitfall for human traders.
In AMGN's case, the AI trading robot's strategy relied on the MACD's positive turn, an indicator that was substantiated by historical trends. It's a reminder that, while technical analysis cannot predict future price movements with 100% accuracy, it can provide valuable statistical insights into potential market behavior.
The AI trading robot's impressive 4.47% profit generation last week for AMGN illustrates the promising potential of AI in stock market trading. It serves as a testament to the potential synergy of technology and financial market, delivering significant returns based on reliable technical analysis tools like MACD. As the field of AI continues to evolve, we can expect an even greater precision and consistency in trading strategy execution, marking a new era of algorithmic trading.
The RSI Oscillator for AMGN moved out of oversold territory on September 26, 2024. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 31 similar instances when the indicator left oversold territory. In of the 31 cases the stock moved higher. This puts the odds of a move higher at .
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where AMGN advanced for three days, in of 287 cases, the price rose further within the following month. The odds of a continued upward trend are .
AMGN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Momentum Indicator moved below the 0 level on October 23, 2024. You may want to consider selling the stock, shorting the stock, or exploring put options on AMGN as a result. In of 82 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for AMGN turned negative on October 21, 2024. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at .
AMGN moved below its 50-day moving average on October 14, 2024 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for AMGN crossed bearishly below the 50-day moving average on October 01, 2024. This indicates that the trend has shifted lower and could be considered a sell signal. In of 19 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AMGN declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 68, placing this stock better than average.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: AMGN's P/B Ratio (24.331) is slightly higher than the industry average of (5.632). P/E Ratio (22.661) is within average values for comparable stocks, (48.974). Projected Growth (PEG Ratio) (2.526) is also within normal values, averaging (3.004). Dividend Yield (0.031) settles around the average of (0.164) among similar stocks. P/S Ratio (5.402) is also within normal values, averaging (3.643).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. AMGN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a manufacturer of human therapeutic products based on cellular biology
Industry PharmaceuticalsMajor